By Carlo Martuscelli

GlaxoSmithKline PLC (GSK.LN) said Friday that its majority-owned subsidiary, ViiV Healthcare, has submitted a marketing authorization application for a HIV therapy to the European Medicines Agency.

The U.K. pharmaceutical company said the application was submitted for the combined treatment--consisting of dolutegravir and lamivudine--based on the results of the two Gemini studies that included 1,400 adults with the disease.

"This regulatory submission, if approved, will make available a two-drug regimen option with dolutegravir and lamivudine instead of the traditional three-drug regimen and is an important step in the evolution of HIV treatment," said Deborah Waterhouse, chief executive officer of ViiV Healthcare.

ViiV Healthcare is majority-owned by Glaxo, with Pfizer Inc. (PFE) and Shionogi Limited also holding stakes.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

September 14, 2018 04:28 ET (08:28 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Gsk.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Gsk.